Series A · Biotech · Cambridge, United Kingdom · Founded 2021 · 20–50 employees
Constructive Bio is a Cambridge-based biotech that has developed revolutionary synthetic biology technology to rewrite genomes and expand the genetic code. The company uses synthetic E. coli and over 300 non-canonical amino acids to manufacture peptide therapeutics via fermentation, creating biomolecules with properties previously impossible to produce sustainably. Built on groundbreaking research from Professor Jason Chin's lab at MRC Laboratory of Molecular Biology, the technology has been published in Nature, Science, and Nature Chemistry. The company recently raised $58 million in Series A funding, bringing total capital to $75 million, and has demonstrated scalable production of multifunctional proteins at commercial levels.